Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D E Furst

Showing results (31-40 of 251) with videos related to

Pageof 26
Sort By:
Rheumatic Diseases Clinics of North America|May 1, 1994
Predictors of worsening clinical variables and outcomes in rheumatoid arthritisD E Furst
Zeitschrift Fur Rheumatologie|May 5, 1998
Clinical pharmacology of combination disease-controlling (DCART/DMARD) therapy in rheumatoid arthritisD E Furst
The Journal of Rheumatology. Supplement|December 1, 1985
Clinical pharmacology of very low dose methotrexate for use in rheumatoid arthritisD E Furst
Seminars in Arthritis and Rheumatism|October 1, 1990
Proposition: methotrexate should not be the first second-line agent to be used in rheumatoid arthritis if NSAIDs failD E Furst
Journal of Clinical Pharmacology|June 1, 1988
Comments on possible long-term consequences of nonsteroidal anti-inflammatory useD E Furst
The Journal of Rheumatology. Supplement|March 1, 1996
Clinical pharmacology of combination DMARD therapy in rheumatoid arthritisD E Furst
The American Journal of Medicine|July 13, 1984
Use of ibuprofen in unusual circumstancesD E Furst
Seminars in Arthritis and Rheumatism|June 1, 1997
Meloxicam: selective COX-2 inhibition in clinical practiceD E Furst
Seminars in Arthritis and Rheumatism|June 1, 1994
Should methotrexate be used to treat early rheumatoid arthritis?D E Furst
Rheumatology (Oxford, England)|September 17, 2008
Outcome measures in rheumatologic clinical trials and systemic sclerosisD E Furst
Pageof 26

Showing results (31-40 of 251) with videos related to

Sort By:
Pageof 26
Rheumatic Diseases Clinics of North America|May 1, 1994
Predictors of worsening clinical variables and outcomes in rheumatoid arthritisD E Furst
Zeitschrift Fur Rheumatologie|May 5, 1998
Clinical pharmacology of combination disease-controlling (DCART/DMARD) therapy in rheumatoid arthritisD E Furst
The Journal of Rheumatology. Supplement|December 1, 1985
Clinical pharmacology of very low dose methotrexate for use in rheumatoid arthritisD E Furst
Seminars in Arthritis and Rheumatism|October 1, 1990
Proposition: methotrexate should not be the first second-line agent to be used in rheumatoid arthritis if NSAIDs failD E Furst
Journal of Clinical Pharmacology|June 1, 1988
Comments on possible long-term consequences of nonsteroidal anti-inflammatory useD E Furst
The Journal of Rheumatology. Supplement|March 1, 1996
Clinical pharmacology of combination DMARD therapy in rheumatoid arthritisD E Furst
The American Journal of Medicine|July 13, 1984
Use of ibuprofen in unusual circumstancesD E Furst
Seminars in Arthritis and Rheumatism|June 1, 1997
Meloxicam: selective COX-2 inhibition in clinical practiceD E Furst
Seminars in Arthritis and Rheumatism|June 1, 1994
Should methotrexate be used to treat early rheumatoid arthritis?D E Furst
Rheumatology (Oxford, England)|September 17, 2008
Outcome measures in rheumatologic clinical trials and systemic sclerosisD E Furst
Pageof 26